273 related articles for article (PubMed ID: 19835668)
1. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.
Marcus MM; Wiker C; Frånberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
Int J Neuropsychopharmacol; 2010 Aug; 13(7):891-903. PubMed ID: 19835668
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
Wadenberg ML; Wiker C; Svensson TH
Int J Neuropsychopharmacol; 2007 Apr; 10(2):191-202. PubMed ID: 16707032
[TBL] [Abstract][Full Text] [Related]
3. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.
Marcus MM; Jardemark KE; Wadenberg ML; Langlois X; Hertel P; Svensson TH
Int J Neuropsychopharmacol; 2005 Sep; 8(3):315-27. PubMed ID: 15857571
[TBL] [Abstract][Full Text] [Related]
4. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.
Marcus MM; Jardemark K; Malmerfelt A; Björkholm C; Svensson TH
Neuropsychopharmacology; 2010 Aug; 35(9):1952-61. PubMed ID: 20463659
[TBL] [Abstract][Full Text] [Related]
5. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence.
Marcus MM; Jardemark K; Malmerfelt A; Gertow J; Konradsson-Geuken A; Svensson TH
Synapse; 2012 Apr; 66(4):277-90. PubMed ID: 22121030
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.
Jardemark K; Marcus MM; Malmerfelt A; Shahid M; Svensson TH
Psychopharmacology (Berl); 2012 May; 221(1):115-31. PubMed ID: 22068461
[TBL] [Abstract][Full Text] [Related]
7. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism.
Hertel P; Nomikos GG; Schilström B; Arborelius L; Svensson TH
Neuropsychopharmacology; 1997 Jul; 17(1):44-55. PubMed ID: 9194049
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.
Hertel P; Fagerquist MV; Svensson TH
Science; 1999 Oct; 286(5437):105-7. PubMed ID: 10506554
[TBL] [Abstract][Full Text] [Related]
9. α2-Adrenoceptors are targets for antipsychotic drugs.
Brosda J; Jantschak F; Pertz HH
Psychopharmacology (Berl); 2014 Mar; 231(5):801-12. PubMed ID: 24488407
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of α2 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats.
Jacobson SM; Prus AJ
Behav Pharmacol; 2010 Oct; 21(7):654-9. PubMed ID: 20729715
[TBL] [Abstract][Full Text] [Related]
11. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
Hertel P; Nomikos GG; Svensson TH
Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
[TBL] [Abstract][Full Text] [Related]
12. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats.
Wadenberg ML; Hertel P; Fernholm R; Hygge Blakeman K; Ahlenius S; Svensson TH
J Neural Transm (Vienna); 2000; 107(10):1229-38. PubMed ID: 11129112
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
Eltayb A; Wadenberg ML; Svensson TH
Biol Psychiatry; 2005 Aug; 58(4):337-43. PubMed ID: 16102547
[TBL] [Abstract][Full Text] [Related]
15. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
16. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
17. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Kalkman HO; Loetscher E
Eur J Pharmacol; 2003 Feb; 462(1-3):33-40. PubMed ID: 12591093
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496
[TBL] [Abstract][Full Text] [Related]
19. Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate).
Morimoto T; Hashimoto K; Yasumatsu H; Tanaka H; Fujimura M; Kuriyama M; Kimura K; Takehara S; Yamagami K
Neuropsychopharmacology; 2002 Apr; 26(4):456-67. PubMed ID: 11927170
[TBL] [Abstract][Full Text] [Related]
20. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
Ballmaier M; Zoli M; Mazzoncini R; Gennarelli M; Spano F
Psychopharmacology (Berl); 2001 Dec; 159(1):105-10. PubMed ID: 11797077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
